PROTAC Shrinks Mutated Prostate Tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Advanced prostate cancer remains a significant health concern.
• Targeted therapies are crucial for improving patient outcomes.
• Proteolysis-targeting chimeras (PROTACs) represent a novel therapeutic modality.

Purpose of the Study:

• To evaluate the efficacy of bavdegalutamide, a clinical-stage PROTAC, in advanced prostate cancer.
• To identify specific molecular subtypes of prostate cancer that respond best to bavdegalutamide.
• To present data from a phase I/II clinical trial.

Main Methods:

• Phase I/II clinical trial design.
• Patient stratification based on molecular alterations, specifically androgen receptor (AR) mutations (T878X, H875Y).
• Assessment of antitumor activity and safety of bavdegalutamide.

Main Results:

• Bavdegalutamide demonstrated antitumor activity in patients with advanced prostate cancer.
• The highest efficacy was observed in patients with specific AR mutations: T878X or H875Y.
• The study provides early clinical evidence for bavdegalutamide's targeted action.

Conclusions:

• Bavdegalutamide is a clinically advanced proteolysis-targeting chimera with potential in advanced prostate cancer.
• Its efficacy is most pronounced in molecularly defined subtypes harboring T878X or H875Y androgen receptor mutations.
• These findings support further development of bavdegalutamide for precision oncology in prostate cancer.